1-4 of 4
Erik Slinger
Close
Sort by
Journal Articles

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Erik Slinger, PhD, Sriram Balasubramanian, PhD, Joel D. Leverson, PhD, Eric Eldering, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3018.
https://doi.org/10.1182/blood.V130.Suppl_1.3018.3018
Published: 2017
Journal Articles

CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa

Erik Slinger, PhD, Felix Wensveen, PhD, Arnon P. Kater, MD PhD, Eric Eldering, PhD
Journal: Blood
Blood (2015) 126 (23): 4144.
https://doi.org/10.1182/blood.V126.23.4144.4144
Published: 2015
Journal Articles

The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL

Martijn H.A. van Attekum, MD, Sanne Terpstra, Emilie Reinen, Marieke Von Lindern, PhD, Erik Slinger, PhD, Eldering Eric, PhD, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1715.
https://doi.org/10.1182/blood.V126.23.1715.1715
Published: 2015
Journal Articles

Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model

Brief Report
Valeria Lascano, Marco Guadagnoli, Jan G. Schot, Dieuwertje M. Luijks, Jeroen E. J. Guikema, Katherine Cameron, Michael Hahne, Steven Pals, Erik Slinger, Thomas J. Kipps, Marinus H. J. van Oers, Eric Eldering, Jan Paul Medema, Arnon P. Kater
Journal: Blood
Blood (2013) 122 (24): 3960–3963.
https://doi.org/10.1182/blood-2013-04-497693
Published: 2013
Includes: Supplemental data